Please see full Important Safety Information below in the pinned post and at www.tagrissohcp.com/#isi
This product information is intended for US Healthcare Professionals only.
TAGRISSO is an AstraZeneca brand and is not associated with any individual users on LinkedIn.
Please see full Prescribing Information including Patient Information by visiting tagrissohcp.az/piFB
You may report side effects related to AstraZeneca products by visiting
https://us-aereporting.astrazeneca.com/adverse-events.html
US-68753 Last Updated 10/22
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://TagrissoHCP.com
- Competitors
- OPDIVO® (nivolumab) US HCP, PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) HCP, ZERBAXA® (ceftolozane and tazobactam) HCP, KEYTRUDA® (pembrolizumab) HCP, KISQALI HCP, ENHERTU® (fam-trastuzumab deruxtecan-nxki) HCP, IMFINZI® (durvalumab) HCP, QUVIVIQ® (daridorexant), BENLYSTA (belimumab), Entyvio (vedolizumab).
Tagrisso® (Osimertinib) Hcp Questions
Tagrisso® (Osimertinib) Hcp's website is http://TagrissoHCP.com
Tagrisso® (Osimertinib) Hcp's LinkedIn profile is https://www.linkedin.com/company/tagrissohcp
Tagrisso® (Osimertinib) Hcp's industry is
Pharmaceutical Manufacturing
Tagrisso® (Osimertinib) Hcp's top competitors are
Opdivo® (Nivolumab) Us Hcp,
Pluvicto® (Lutetium Lu 177 Vipivotide Tetraxetan) Hcp,
Zerbaxa® (Ceftolozane And Tazobactam) Hcp,
Keytruda® (Pembrolizumab) Hcp,
Kisqali Hcp,
Enhertu® (Fam-Trastuzumab Deruxtecan-Nxki) Hcp,
Imfinzi® (Durvalumab) Hcp,
Quviviq® (Daridorexant),
Benlysta (Belimumab),
Entyvio (Vedolizumab).
Tagrisso® (Osimertinib) Hcp's categories are Pharmaceutical Manufacturing
